Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 9:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: HEC Placebo Clear all
Completed No phase listed Observational Accepts healthy volunteers

Microbicides Acceptability Among Sexually Active Young Women

NCT00490152
View directory record Official record
Conditions
HIV Infections
Interventions
Automated diary system
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
2
States / cities
Tampa, Florida • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Sep 4, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Acceptability of SPL7013 Gel (VivaGel™) in Sexually Active Women

NCT00442910
View directory record Official record
Conditions
Healthy
Interventions
3% SPL7013 Gel (VivaGel), Placebo Gel, HEC Placebo Gel
Drug
Lead sponsor
Starpharma Pty Ltd
Industry
Eligibility
18 Years to 24 Years · Female only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
2
States / cities
Tampa, Florida • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2010 · Synced Sep 4, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

NCT03578081
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Palonosetron Hydrochloride, Ondansetron Hydrochloride, Dexamethasone, Fosaprepitant Dimeglumine, Olanzapine, Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
565
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Kingman, Arizona + 372 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 4, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE)

NCT04370548
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
DARE-BV1clindamycin phosphate vaginal gel, 2%
Drug
Lead sponsor
Daré Bioscience, Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
10
States / cities
Tucson, Arizona • Denver, Colorado • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Sep 4, 2026, 9:42 PM EDT
Terminated Phase 3 Interventional

Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers

NCT01830348
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
DSC127, placebo vehicle gel
Drug
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
25
States / cities
Mobile, Alabama • Fair Oaks, California • Fresno, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 4, 2026, 9:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers of Protocol Compliance and Product Adherence

NCT01804023
View directory record Official record
Conditions
HIV Prevention
Interventions
HEC placebo gel applicators
Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Sep 4, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Male Tolerance Study of Dapivirine Gel Following Multiple Topical Penile Exposures

NCT01277640
View directory record Official record
Conditions
Topical Penile Exposures
Interventions
dapivirine, matched placebo, universal placebo
Drug
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Sep 4, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults

NCT03239483
View directory record Official record
Conditions
HIV Infections
Interventions
Dapivirine gel, Placebo gel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Sep 4, 2026, 9:42 PM EDT
Terminated Phase 3 Interventional

Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers

NCT01849965
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
DSC127, placebo vehicle gel, Standard of Care gel, Aquasite
Drug
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Mesa, Arizona • Phoenix, Arizona • Castro Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 4, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy

NCT02116530
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Olanzapine, Chemotherapy (cisplatin or cyclophosphamide and doxorubicin), Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant), Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
177
States / cities
Anchorage, Alaska • Burbank, California • Dublin, California + 109 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 4, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study Of The Caya® Diaphragm Used With ContraGel®

NCT02462954
View directory record Official record
Conditions
Contraception
Interventions
ContraGel, HEC Universal Placebo gel
Device
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Sep 4, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC

NCT02106494
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
APF530, Ondansetron, Ondansetron placebo, APF530 placebo, Fosaprepitant, Dexamethasone
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years to 87 Years
Enrollment
942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Phoenix, Arizona • Downey, California • Riverside, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 4, 2026, 9:42 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

An Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Assessment of Bare Spots

NCT00214812
View directory record Official record
Conditions
HIV Infections
Interventions
HEC placebo gel
Drug
Lead sponsor
Biosyn
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 24, 2005 · Synced Sep 4, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics and Acceptability of PC-1005 for Vaginal Use

NCT02033109
View directory record Official record
Conditions
HIV
Interventions
PC-1005, HEC gel
Drug
Lead sponsor
Population Council
Other
Eligibility
19 Years to 49 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Sep 4, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy

NCT01499849
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant, Granisetron, dexamethasone, Placebo
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Sep 4, 2026, 9:42 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Dapivirine Gel Rectal Safety and PK Study

NCT03044379
View directory record Official record
Conditions
HIV 1 Infection
Interventions
Dapivirine gel (0.05%), Universal HEC placebo gel
Drug · Other
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 4, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety of USB005 in Healthy Volunteers

NCT03615196
View directory record Official record
Conditions
Healthy Volunteers
Interventions
USB005 (aclerastide) Ophthalmic Solution, USB005 Ophthalmic Solution Placebo
Drug
Lead sponsor
US Biotest, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Sep 4, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Microbicide Safety and Acceptability in Young Men

NCT01283360
View directory record Official record
Conditions
High Risk MSM, HIV Negative, 18-30 Years of Age
Interventions
HEC Placebo Gel, Tenofovir 1% Gel
Other · Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Sep 4, 2026, 9:42 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Safety and Acceptability of Tenofovir 1% Gel in Adolescent Females

NCT02245945
View directory record Official record
Conditions
HIV Prevention
Interventions
TFV 1% vaginal gel, HEC Placebo Gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
15 Years to 17 Years · Female only
Healthy volunteers
Accepts healthy volunteers
U.S. locations
2
States / cities
The Bronx, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Sep 4, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation

NCT01593124
View directory record Official record
Conditions
Vaginal Inflammation, Vaginal Infections
Interventions
Imiquimod, Placebo, Nonoxynol-9
Drug · Other
Lead sponsor
CONRAD
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Sep 4, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet

NCT00984971
View directory record Official record
Conditions
HIV Prevention, HIV Infections
Interventions
Tenofovir, HEC Placebo, Open label tenofovir tablet
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2015 · Synced Sep 4, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally

NCT01575405
View directory record Official record
Conditions
HIV Prevention
Interventions
Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel, Universal HEC Placebo Gel Formulation
Drug
Lead sponsor
Ian McGowan
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Sep 4, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Development of Adherence Biomarkers for Multiple Microbicide and Multipurpose Prevention Technology (MPT) Dosage Forms

NCT02569697
View directory record Official record
Conditions
HIV
Interventions
HEC Placebo gel, Placebo Intravaginal Ring, Placebo Vaginal Film, Placebo Vaginal Insert
Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Sep 4, 2026, 9:42 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States

NCT00799058
View directory record Official record
Conditions
HIV-1 Infections
Interventions
dapivirine 4789, dapivirine gel 4759, Drug placebo
Drug
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
5
States / cities
Birmingham, Alabama • Torrance, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Sep 4, 2026, 9:42 PM EDT